Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (the "Company") reports material definitive agreements entered into on March 14, 2019. The Company, an emerging growth company incorporated in Delaware, executed three primary transactions to secure capital: a common stock purchase agreement with Aspire Capital Fund, LLC; a debt facility with Innovatus Life Sciences Lending Fund I, LP and East West Bank; and a common stock purchase agreement with entities affiliated with Innovatus.
Key Financial Metrics and Capital Structure
The filing details the following capital raises and debt commitments:
- Aspire Capital Equity: Immediate proceeds of $1.0 million from the sale of 272,479 shares at $3.67 per share. A commitment exists for Aspire to purchase up to an additional $9.0 million over 30 months.
- Innovatus Debt Facility: A total commitment of up to $30.0 million, consisting of term loans up to $25.0 million and a revolving line of credit up to $5.0 million.
- Innovatus Equity: Immediate proceeds of $1.5 million from the sale of 406,504 shares at $3.69 per share to Innovatus-affiliated investors.
- Commitment Shares: The Company issued 69,444 shares to Aspire Capital as consideration for entering the purchase agreement.
- Warrants: The Company agreed to issue warrants to Innovatus to purchase up to 202,482 shares in total (across three tranches) at an exercise price of $4.63 per share.
The filing does not provide current revenue, profit, cash flow, or margin data, as this is a current report regarding specific agreements rather than a periodic financial statement.
Material Changes and Transaction Terms
The Company has significantly altered its capital structure through the following mechanisms:
- Aspire Purchase Agreement: The Company retains sole discretion to direct purchases. The purchase price is the lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding ten trading days. A floor price of $0.25 per share applies. The Company may also utilize a Volume-Weighted Average Price (VWAP) notice for up to 30% of daily trading volume at 97% of the VWAP.
- Innovatus Loan Agreement:
- Tranches: Term A-1 ($17.5 million) is expected to fund upon customary conditions. Term A-2 ($2.5 million) and Term B ($5.0 million) are contingent on financial milestones.
- Interest: Floating rate equal to the greater of 5.50% or the Bank's prime rate, plus 4.75% (3.0% payable in-kind).
- Repayment: Interest-only for 36 months, followed by a 24-month amortization. Maturity is five years from the initial funding date.
- Fees: Includes a 3.75% final fee on the total commitment, a 1.25% facility fee on funded amounts, and prepayment fees ranging from 1% to 3% depending on the timing of prepayment.
Restrictions and Covenants
The Loan Agreement imposes significant restrictions on the Company, including:
- Prohibition on declaring dividends or repurchasing equity.
- Restrictions on incurring additional indebtedness, liens, or engaging in mergers and acquisitions.
- Cash Covenant: The Company must maintain minimum unrestricted cash in a controlled account equal to the greater of $3.0 million or the trailing three months' cash used for operating and investing activities (minus Revolver availability), with a hard floor of $2.0 million.
- Collateral: Obligations are secured by substantially all Company assets, including intellectual property.
Outlook, Risks, and Contingencies
Use of Proceeds: Proceeds from the Aspire and Innovatus equity agreements are designated for working capital and general corporate purposes. The filing does not specify a detailed operational outlook or revenue guidance.
Risks and Contingencies:
- Dilution: The agreements involve the issuance of significant equity (immediate and potential future shares) and warrants, which may dilute existing shareholders.
- Debt Service: The Company faces substantial future cash outflows for interest and principal repayment, including in-kind interest accruals.
- Operational Constraints: The debt covenants limit the Company's financial flexibility regarding dividends, additional debt, and strategic transactions.
- Market Price Floor: The Aspire agreement cannot be utilized if the stock price falls below $0.25.
Key Facts for Investor Verification
- Verify the current stock price relative to the $0.25 floor price for the Aspire agreement and the $4.63 warrant exercise price.
- Confirm the Company's current unrestricted cash balance to ensure compliance with the $2.0 million - $3.0 million minimum cash covenant.
- Monitor the achievement of financial milestones required to unlock the $7.5 million in contingent term loans (Term A-2 and Term B).
- Review the total potential dilution from the 69,444 commitment shares, immediate equity sales, and the 202,482 warrant shares.
- Assess the impact of the 3.75% final fee and prepayment penalties on the total cost of the $25.0 million term loan commitment.